Check out Tatva Chintan Pharma IPO GMP aka IPO Grey Market Premium, Kostak rates, and Subject to Sauda rates as of today. Tatva Chintan Pharma IPO GMP is going good around 900-1000 level.
Tatva Chintan Pharma IPO to hit the market on 16 July 2021 AND closes on 20 July 2021 The company to raise ₹450 crore via initial public offer, ₹225 crore via fresh issue and ₹225 crore stake sale of their existing share holder. They are one of the largest manufacturer of SDAs for zeolites in India, based in Gujarat. The financial looks good and we can expect it to zoom in the grey market. The price band is fixed at ₹1073 to ₹1083 per equity share. The Tatva Chintan Pharma IPO to list on NSE and BSE.
What is Tatva Chintan Pharma IPO GMP Today?
The Tatva Chintan Pharma IPO GMP aka grey market premium is ₹1000.
What is Tatva Chintan Pharma IPO Kostak Rates Today?
The Tatva Chintan Pharma IPO kostak rate is ₹400.
What is Tatva Chintan Pharma IPO Subject to Sauda Price Today?
The Tatva Chintan Pharma IPO subject to sauda rates is ₹8000.
Tatva Chintan Pharma IPO Expected Returns?
The Tatva Chintan Pharma expected return is 90%.
Tatva Chintan Pharma IPO GMP Rates day by day with Kotak rates.
| Date |
GMP |
Kostak | Subject to |
| 23 July | ₹1000 | ₹400 | ₹8000 |
| 22 July | ₹900 | ₹300 | ₹8000 |
| 21 July | ₹870 | ₹450 | ₹7500 |
| 20 July | ₹750 | ₹450 | ₹7500 |
| 19 July | ₹750 | ₹450 | ₹7500 |
| 18 July | ₹750 | ₹450 | ₹7500 |
| 17 July | ₹750 | ₹450 | ₹7500 |
| 16 July | ₹690 | ₹350 | ₹7000 |
| 15 July | ₹650 | ₹300 | ₹6000 |
| 14 July | ₹570 | ₹400 | ₹5000 |
| 13 July | ₹480 | ₹350 | ₹5000 |
| 12 July | ₹570 | ₹350 | ₹5000 |
| 11 July | ₹450 | ₹350 | ₹5000 |
| 10 July | ₹450 | ₹350 | ₹5000 |
| 09 July | ₹450 | ₹350 | ₹5000 |
| 08 July | ₹0 | ₹0 | ₹0 |
| 07 July | ₹0 | ₹0 | ₹0 |
Read Also:
About Tatva Chintan Pharma
We are a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (“SDAs”), phase transfer catalysts (“PTCs”), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (“PASC”). Our Company is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally. (Source: F&S Report) In addition, our Company is one of the leading global producers of an entire range of PTCs in India and one of the key producers across the globe. (Source: F&S Report) As a manufacturer of specialty chemicals, we focus on application of our products which form a key ingredient to our customers’ manufacturing and industrial processes. For instance, our SDA and PTC products have various applications in green chemistry, which is pertinent considering the growing focus on green and sustainable technologies. We continuously strive to improve our processes and infrastructure to help reduce our impact on the environment and have accordingly, undertaken various ‘green’ chemistry processes such as electrolysis. Considering the wide application of our products, we serve customers across various industries, including the automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavour and fragrances industries. Apart from our customers in India, we also export our products to over 25 countries, including the USA, China, Germany, Japan, South Africa, and the UK.
Our Company is promoted by Chintan Shah, Ajay Patel and Shekhar Somani, who each have over 24 years in the specialty chemicals manufacturing industry and have established strong business relationships with domestic as well as overseas customers. In addition, we are led by a well – qualified and experienced management team, which we believe has demonstrated its ability to manage and grow our operations and has substantial experience in the sectors in which we operate. We believe that the knowledge and experience of our management team provides us with a significant competitive advantage as we seek to grow our business.
Our Company is promoted by Chintan Shah, Ajay Patel and Shekhar Somani, who each have over 24 years in the specialty chemicals manufacturing industry and have established strong business relationships with domestic as well as overseas customers. In addition, we are led by a well – qualified and experienced management team, which we believe has demonstrated its ability to manage and grow our operations and has substantial experience in the sectors in which we operate. We believe that the knowledge and experience of our management team provides us with a significant competitive advantage as we seek to grow our business.
Tatva Chintan Pharma IPO Date & Price Band
| IPO Open: | 16 July 2021 |
| IPO Close: | 20 July 2021 |
| IPO Size: | Approx ₹450 Crores |
| Fresh Issue: | Approx ₹225 Crores |
| Offer for Sale: | Approx ₹225 Crores |
| Face Value: | ₹10 Per Equity Share |
| Price Band: | ₹1073 to ₹1083 Per Share |
| Listing on: | BSE & NSE |
| Retail Portion: | 35% |
| Equity: | - Shares |
| Discount: | N/A |
Tatva Chintan Pharma IPO Market Lot
| Minimum Lot Size: | Minimum 13 Shares |
| Minimum Amount: | ₹14,079 |
| Maximum Lot Size: | Maximum 182 Shares |
| Maximum Amount: | ₹197,106 |
Tatva Chintan Pharma IPO Allotment & Listing
| Basis of Allotment: | 26 July 2021 |
| Refunds: | 27 July 2021 |
| Credit to Demat Account: | 28 July 2021 |
| Listing Date: | 29 July 2021 |
Tatva Chintan Pharma IPO GMP aka Grey Market Premium FAQs:
What is Tatva Chintan Pharma IPO GMP Today?
Tatva Chintan Pharma IPO GMP is ₹1000 as on today.
What is Tatva Chintan Pharma IPO Kostak Rate Today?
Tatva Chintan Pharma IPO Kostak Rate is ₹400 as on today.
What is Tatva Chintan Pharma IPO Subject to Sauda Today?
Tatva Chintan Pharma IPO Subject to Sauda is ₹8000 as on today.
What is Tatva Chintan Pharma IPO Expected Returns?
Tatva Chintan Pharma IPO Expected Returns is 90% .
Disclaimer:
- IPO Grey Market Premium (Tatva Chintan Pharma IPO GMP) mention is valid for the specific date as mentioned in the header.
- We are not buying and selling IPO forms on IPO Grey Market.
- Kostak Rate is the premium one gets by selling his/her IPO application (in an off-market transaction) to someone else even before allotment or listing of the issue.
- Do not subscribe for IPO by just seeing premium Price as it may change anytime before listing. Subscribe only considering Fundamental of the companies.
